Testing Samples to Spot Liver Transplant Problems Early in Adults
Tests blood, urine and tissue samples to find kidney damage, rejection or hepatitis C early.
Key facts
- Who runs it
- Northwestern University
- Where
- Chicago, United StatesSee the site
- Trial code
- Registry title
- Proteogenomic Monitoring and Assessment of Liver Transplant Recipients
- Status
- Recruiting
- People taking part
- 1,000 people, planned
- Started
- Apr 2010
- Expected to end
- Dec 2031
- Type of study
- Observational
- Record updated
- 22 May 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who are having a liver transplant, from a living or deceased donor. It studies blood, urine and tissue samples.
- Age
- 18 years or older
- Sex
- Women and men
- Disease stage
- People having a first or repeat liver transplant from a living or deceased donor.
Main reasons for not taking part
- People who cannot or do not want to give informed consent (or whose guardian cannot or does not want to)
This trial only enrols participants who have had an organ transplant. The registry sentence this rests on: Patients undergoing primary or subsequent living or deceased donor liver transplantation.
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Male and female recipients of all races, ≥18 years of age
- Patients undergoing primary or subsequent living or deceased donor liver transplantation
- Subject and/or guardian must be able to provide informed consent
- Subject and/or guardian must be able to comply with the study protocol
Who cannot take part
- Inability or unwillingness of a participant and/or guardian to provide informed consent
Where in United States
- Northwestern Memorial HospitalChicago, United StatesContact: Misael Villegas, BATaking people
About the trial
What the trial wants to find out
This study is being done to test blood, urine and tissue samples to see if this can help decide if CKD (Chronic Kidney Disease), AR (Acute Rejection) and HCV (Hepatitis C Virus) can be identified in its early stages. CKD damage to the kidneys, AR and HCV all lower the body's ability to function properly. Early detection of these conditions could assist with successful treatment and possibly lead to less repeat organ transplants.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Proteogenomic Monitoring and Assessment of Liver Transplant Recipients
- Plain-language title
- Testing Samples to Spot Liver Transplant Problems Early in AdultsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 22 May 2026